BridgeBio Pharma Quarterly Balance Sheets Chart
Quarterly
|
Annual
BridgeBio Pharma Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||||
| cash and cash equivalents | 748,953,000 | 540,599,000 | 681,101,000 | 266,324,000 | 407,958,000 | 475,222,000 | 375,935,000 | 505,213,000 | 302,438,000 | 407,368,000 | 376,689,000 | 483,235,000 | 470,098,000 | 371,550,000 | 393,772,000 | 180,347,000 | 378,420,000 | 471,176,000 | 356,082,000 | 366,967,000 | 540,919,000 | 757,049,000 | 363,773,000 | 413,973,000 | 293,803,000 |
| marketable securities | 7,939,000 | 39,813,000 | 44,469,000 | 30,869,000 | 34,122,000 | 51,580,000 | 75,080,000 | 218,466,000 | 261,904,000 | ||||||||||||||||
| accounts receivable | 76,868,000 | 115,265,000 | 4,722,000 | 1,213,000 | |||||||||||||||||||||
| inventories | 18,277,000 | 3,954,000 | |||||||||||||||||||||||
| prepaid expenses and other current assets | 60,240,000 | 35,355,000 | 34,743,000 | 38,367,000 | 28,396,000 | 28,108,000 | 24,305,000 | 22,583,000 | 20,546,000 | 25,145,000 | 21,922,000 | 25,661,000 | 32,754,000 | 34,021,000 | 32,446,000 | 31,927,000 | 26,670,000 | 25,534,000 | 35,731,000 | 26,703,000 | 20,996,000 | 19,782,000 | 22,629,000 | 22,102,000 | 12,906,000 |
| total current assets | 912,277,000 | 695,173,000 | 720,692,000 | 444,578,000 | 616,236,000 | 783,424,000 | 477,593,000 | 587,670,000 | 432,884,000 | 552,702,000 | 548,853,000 | 642,219,000 | 771,280,000 | 716,230,000 | 888,858,000 | 639,710,000 | 909,871,000 | 945,114,000 | 642,824,000 | 745,384,000 | 861,935,000 | 924,957,000 | 568,622,000 | 558,155,000 | 306,709,000 |
| investment in nonconsolidated entities | 108,002,000 | 128,191,000 | 143,747,000 | 160,443,000 | |||||||||||||||||||||
| property and equipment | 6,107,000 | 6,698,000 | 7,011,000 | 8,701,000 | 9,840,000 | 11,414,000 | 11,816,000 | 12,413,000 | 13,047,000 | 13,566,000 | 14,569,000 | 15,603,000 | 16,873,000 | 17,182,000 | 30,066,000 | 27,741,000 | 26,272,000 | 22,816,000 | 20,325,000 | 16,182,000 | 15,573,000 | 15,755,000 | 5,625,000 | 2,984,000 | 1,865,000 |
| operating lease right-of-use assets | 6,186,000 | 7,166,000 | 5,767,000 | 6,439,000 | 7,267,000 | 8,052,000 | 8,027,000 | 9,332,000 | 9,814,000 | 10,532,000 | 10,678,000 | 11,738,000 | 12,850,000 | 13,936,000 | 15,907,000 | 17,108,000 | 15,964,000 | 12,997,000 | 16,508,000 | 9,644,000 | 10,465,000 | 8,855,000 | |||
| intangible assets | 29,513,000 | 27,802,000 | 23,926,000 | 24,525,000 | 25,123,000 | 25,721,000 | 26,319,000 | 26,917,000 | 27,515,000 | 28,113,000 | 28,712,000 | 29,310,000 | 29,908,000 | 30,476,000 | 44,934,000 | 46,204,000 | |||||||||
| other assets | 18,105,000 | 16,608,000 | 18,195,000 | 20,291,000 | 18,903,000 | 20,722,000 | 22,625,000 | 18,676,000 | 20,401,000 | 20,767,000 | 20,224,000 | 29,870,000 | 31,322,000 | 35,325,000 | 33,027,000 | 33,054,000 | 49,797,000 | 30,179,000 | 23,931,000 | 16,483,000 | 17,254,000 | 17,022,000 | 26,288,000 | 2,598,000 | 9,471,000 |
| total assets | 1,080,190,000 | 881,638,000 | 919,338,000 | 664,977,000 | 794,375,000 | 849,333,000 | 546,380,000 | 655,008,000 | 503,661,000 | 625,680,000 | 623,036,000 | 728,740,000 | 862,233,000 | 813,149,000 | 1,012,792,000 | 781,524,000 | 1,081,486,000 | 1,093,308,000 | 703,588,000 | 787,693,000 | 905,227,000 | 989,799,000 | 631,679,000 | 640,530,000 | 325,540,000 |
| liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | |||||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||||
| accounts payable | 26,134,000 | 27,525,000 | 9,618,000 | 13,363,000 | 18,126,000 | 4,728,000 | 10,655,000 | 4,472,000 | 3,874,000 | 4,076,000 | 11,558,000 | 10,158,000 | 8,793,000 | 10,107,000 | 11,884,000 | 12,035,000 | 22,329,000 | 10,340,000 | 8,945,000 | 9,839,000 | 12,835,000 | 13,086,000 | 8,852,000 | 10,270,000 | 16,065,000 |
| accrued compensation and benefits | 37,187,000 | 33,447,000 | 58,329,000 | 43,541,000 | 29,056,000 | 32,395,000 | 57,370,000 | 33,735,000 | 28,690,000 | 18,869,000 | 31,256,000 | 24,842,000 | 32,609,000 | 15,458,000 | 37,041,000 | 21,560,000 | 21,865,000 | 20,741,000 | 29,682,000 | 18,755,000 | 13,590,000 | 5,647,000 | 13,317,000 | 7,580,000 | 4,736,000 |
| accrued research and development liabilities | 31,295,000 | 33,630,000 | 34,272,000 | 40,997,000 | 33,178,000 | 40,933,000 | 29,765,000 | 29,244,000 | 28,298,000 | 37,064,000 | 39,803,000 | 44,564,000 | 50,091,000 | 43,342,000 | 44,138,000 | 37,645,000 | 55,620,000 | 33,423,000 | 27,290,000 | 24,901,000 | 37,241,000 | 29,522,000 | 20,896,000 | 13,198,000 | 9,419,000 |
| operating lease liabilities, current portion | 4,782,000 | 5,209,000 | 4,506,000 | 4,600,000 | 4,623,000 | 4,544,000 | 4,128,000 | 4,137,000 | 3,776,000 | 3,674,000 | 3,675,000 | 4,044,000 | 4,310,000 | 4,363,000 | 4,938,000 | 4,999,000 | 4,540,000 | 3,807,000 | 3,795,000 | 3,617,000 | 3,627,000 | 2,510,000 | |||
| deferred revenue, current portion | 10,540,000 | 11,620,000 | 14,604,000 | 11,771,000 | 15,098,000 | 13,957,000 | 6,096,000 | 6,592,000 | 6,210,000 | 6,675,000 | 8,156,000 | 7,518,000 | 7,190,000 | ||||||||||||
| other current liabilities | 65,916,000 | 40,674,000 | |||||||||||||||||||||||
| total current liabilities | 175,854,000 | 152,105,000 | 154,400,000 | 139,216,000 | 134,364,000 | 141,477,000 | 143,844,000 | 106,065,000 | 110,120,000 | 96,596,000 | 121,428,000 | 119,194,000 | 141,160,000 | 103,463,000 | 135,069,000 | 95,823,000 | 131,909,000 | 94,729,000 | 95,648,000 | 75,707,000 | 92,640,000 | 64,914,000 | 60,385,000 | 39,858,000 | 38,705,000 |
| 2031 notes | 563,597,000 | 563,124,000 | |||||||||||||||||||||||
| 2029 notes | 739,874,000 | 739,372,000 | 738,872,000 | 738,376,000 | 737,882,000 | 737,392,000 | 736,905,000 | 736,422,000 | 735,940,000 | 735,463,000 | 734,988,000 | 734,516,000 | 734,047,000 | 733,581,000 | 733,119,000 | 732,659,000 | 732,202,000 | 731,747,000 | |||||||
| 2027 notes | 546,088,000 | 545,628,000 | 545,173,000 | 544,719,000 | 544,270,000 | 543,823,000 | 543,379,000 | 542,938,000 | 542,501,000 | 542,065,000 | 541,634,000 | 541,205,000 | 540,779,000 | 540,355,000 | 539,934,000 | 539,517,000 | 539,102,000 | 538,690,000 | 383,436,000 | 378,502,000 | 373,651,000 | 368,923,000 | |||
| term loan | 437,337,000 | 436,221,000 | 435,447,000 | 434,717,000 | 446,445,000 | 441,721,000 | 440,496,000 | 435,764,000 | 430,993,000 | 422,972,000 | 418,353,000 | 434,114,000 | |||||||||||||
| deferred royalty obligations | 813,959,000 | ||||||||||||||||||||||||
| operating lease liabilities, net of current portion | 4,025,000 | 4,915,000 | 4,696,000 | 5,833,000 | 7,059,000 | 8,297,000 | 8,981,000 | 9,812,000 | 10,916,000 | 11,904,000 | 12,274,000 | 13,000,000 | 14,276,000 | 15,494,000 | 17,428,000 | 18,683,000 | 18,022,000 | 13,862,000 | 14,677,000 | 8,236,000 | 9,117,000 | 8,678,000 | |||
| deferred revenue, net of current portion | 14,667,000 | 17,508,000 | 17,095,000 | 18,627,000 | 16,961,000 | 19,890,000 | |||||||||||||||||||
| other long-term liabilities | 545,000 | 352,000 | 286,000 | 377,000 | 485,000 | 595,000 | 9,361,000 | 11,785,000 | 13,326,000 | 17,501,000 | 26,643,000 | 28,226,000 | 28,631,000 | 26,829,000 | 22,069,000 | 27,578,000 | |||||||||
| total liabilities | 2,858,609,000 | 2,520,303,000 | 2,376,950,000 | 1,883,369,000 | 1,876,468,000 | 1,886,191,000 | 1,888,915,000 | 1,848,743,000 | 1,853,299,000 | 1,839,293,000 | 1,867,960,000 | 1,859,113,000 | 1,877,246,000 | 1,853,836,000 | 1,878,371,000 | 1,517,398,000 | 1,537,111,000 | 1,481,402,000 | 595,702,000 | 569,306,000 | 577,715,000 | 537,728,000 | 155,703,000 | 116,263,000 | 114,049,000 |
| commitments and contingencies | |||||||||||||||||||||||||
| redeemable convertible noncontrolling interests | -445,000 | -227,000 | 142,000 | 645,000 | -223,000 | 525,000 | 478,000 | 1,403,000 | 333,000 | -204,000 | -1,589,000 | -2,388,000 | -1,499,000 | 336,000 | 1,423,000 | 2,967,000 | 1,865,000 | 1,271,000 | 1,630,000 | 2,574,000 | 1,906,000 | 3,053,000 | 2,243,000 | 2,570,000 | 175,000 |
| stockholders’ deficit: | |||||||||||||||||||||||||
| undesignated preferred stock, 0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | |||||||||||||||||||||||||
| common stock | 198,000 | 197,000 | 196,000 | 195,000 | 194,000 | 193,000 | 181,000 | 180,000 | 168,000 | 167,000 | 157,000 | 156,000 | 154,000 | 154,000 | 154,000 | 153,000 | 153,000 | 152,000 | 125,000 | 125,000 | 125,000 | 124,000 | 124,000 | 117,000 | |
| treasury stock | -323,276,000 | -323,276,000 | -275,000,000 | -275,000,000 | -275,000,000 | -275,000,000 | -275,000,000 | -275,000,000 | -275,000,000 | -275,000,000 | -275,000,000 | -275,000,000 | -275,000,000 | -275,000,000 | -275,000,000 | -275,000,000 | -130,308,000 | -125,000,000 | -75,000,000 | -75,000,000 | -75,000,000 | -75,000,000 | |||
| additional paid-in capital | 1,980,805,000 | 1,938,369,000 | 1,903,155,000 | 1,876,091,000 | 1,851,058,000 | 1,820,994,000 | 1,481,032,000 | 1,459,596,000 | 1,128,100,000 | 1,106,635,000 | 938,703,000 | 917,333,000 | 892,960,000 | 867,596,000 | 841,530,000 | 821,220,000 | 799,679,000 | 767,117,000 | 1,021,344,000 | 1,006,944,000 | 992,691,000 | 986,746,000 | 848,107,000 | 826,062,000 | |
| accumulated other comprehensive income | 1,000 | 8,000 | 5,000 | -4,000 | 2,000 | 31,000 | 34,000 | 63,000 | -132,000 | 19,000 | 36,000 | -57,000 | 192,000 | 461,000 | 858,000 | 726,000 | 254,000 | 152,000 | |||||||
| accumulated deficit | -3,445,588,000 | -3,263,685,000 | -3,096,263,000 | -2,831,213,000 | -2,669,173,000 | -2,595,717,000 | -2,560,501,000 | -2,392,353,000 | -2,215,354,000 | -2,057,455,000 | -1,918,149,000 | -1,780,558,000 | -1,643,219,000 | -1,633,363,000 | -1,436,966,000 | -1,289,789,000 | -1,133,854,000 | -1,037,506,000 | -888,755,000 | -768,774,000 | -652,915,000 | -531,881,000 | -440,031,000 | -366,573,000 | -326,068,000 |
| total bridgebio stockholders’ deficit | -1,787,860,000 | -1,648,395,000 | -1,467,904,000 | -1,229,922,000 | -1,092,925,000 | -1,049,528,000 | -1,354,257,000 | -1,207,543,000 | -1,362,023,000 | -1,225,665,000 | -1,254,617,000 | -1,138,417,000 | -1,025,532,000 | -1,040,996,000 | |||||||||||
| noncontrolling interests | 9,886,000 | 9,957,000 | 10,150,000 | 10,885,000 | 11,055,000 | 12,145,000 | 11,244,000 | 12,405,000 | 12,052,000 | 12,256,000 | 11,282,000 | 10,432,000 | 12,018,000 | -27,000 | 3,412,000 | 4,556,000 | 6,804,000 | 5,929,000 | 48,350,000 | 52,057,000 | 59,847,000 | 68,303,000 | 65,279,000 | 61,939,000 | 48,391,000 |
| total stockholders’ deficit | -1,777,974,000 | -1,638,438,000 | -1,457,754,000 | -1,219,037,000 | -1,081,870,000 | -1,037,383,000 | -1,343,013,000 | -1,195,138,000 | -1,349,971,000 | -1,213,409,000 | -1,243,335,000 | -1,127,985,000 | -1,013,514,000 | -1,041,023,000 | |||||||||||
| total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | 1,080,190,000 | 881,638,000 | 919,338,000 | 664,977,000 | 794,375,000 | 849,333,000 | 546,380,000 | 655,008,000 | 503,661,000 | 625,680,000 | 623,036,000 | 728,740,000 | 862,233,000 | 813,149,000 | |||||||||||
| deferred royalty obligation | 497,299,000 | 479,091,000 | |||||||||||||||||||||||
| investments in equity securities | |||||||||||||||||||||||||
| restricted cash | 126,000 | 139,409,000 | 139,409,000 | 131,000 | 16,653,000 | 16,652,000 | 19,930,000 | 25,503,000 | 37,930,000 | ||||||||||||||||
| accrued professional and other accrued liabilities | 33,071,000 | 24,944,000 | 34,283,000 | 44,920,000 | 35,830,000 | 27,885,000 | 39,272,000 | ||||||||||||||||||
| receivables from licensing and collaboration agreements | 478,000 | 660,000 | 235,494,000 | ||||||||||||||||||||||
| investment in nonconsolidated entity | 117,006,000 | ||||||||||||||||||||||||
| investment in equity securities | 58,949,000 | 38,052,000 | 50,487,000 | 49,803,000 | 43,653,000 | 33,662,000 | 27,141,000 | 37,772,000 | 49,148,000 | 17,707,000 | 18,894,000 | ||||||||||||||
| receivable from licensing and collaboration agreements | 1,751,000 | 5,170,000 | 8,614,000 | 10,761,000 | 17,079,000 | 24,581,000 | 22,821,000 | 10,983,000 | 19,749,000 | 7,710,000 | 35,363,000 | ||||||||||||||
| accrued professional services | 4,015,000 | 1,790,000 | 4,230,000 | 6,183,000 | 5,411,000 | 6,786,000 | 4,976,000 | 6,378,000 | 4,518,000 | 5,579,000 | 4,706,000 | 8,609,000 | 3,145,000 | 2,222,000 | |||||||||||
| other accrued liabilities | 22,223,000 | 25,190,000 | 23,838,000 | 31,984,000 | 24,782,000 | 30,282,000 | 14,608,000 | 21,177,000 | 18,254,000 | 13,349,000 | 8,691,000 | 11,462,000 | 7,465,000 | 3,020,000 | 4,789,000 | 4,188,000 | |||||||||
| accumulated other comprehensive loss | -12,000 | -328,000 | -348,000 | -427,000 | -383,000 | ||||||||||||||||||||
| short-term marketable securities | 393,743,000 | 419,264,000 | 459,243,000 | 447,942,000 | 251,011,000 | 343,714,000 | 300,020,000 | 148,126,000 | 182,220,000 | 122,080,000 | |||||||||||||||
| liabilities, redeemable convertible noncontrolling interests and stockholders’ equity | |||||||||||||||||||||||||
| leo call option liability | 5,550,000 | 5,198,000 | 5,276,000 | 3,539,000 | 4,078,000 | 4,021,000 | 4,297,000 | ||||||||||||||||||
| term loans, current portion | 3,646,000 | 1,458,000 | |||||||||||||||||||||||
| term loans, net of current portion | 430,752,000 | 103,138,000 | 102,611,000 | 90,762,000 | 92,421,000 | ||||||||||||||||||||
| stockholders’ equity | |||||||||||||||||||||||||
| total bridgebio stockholders’ equity | -870,414,000 | -743,397,000 | -464,294,000 | -395,294,000 | 57,906,000 | ||||||||||||||||||||
| total stockholders’ equity | -867,002,000 | -738,841,000 | -457,490,000 | -389,365,000 | 106,256,000 | ||||||||||||||||||||
| total liabilities, redeemable convertible noncontrolling interests and stockholders’ equity | 1,012,792,000 | 781,524,000 | 1,081,486,000 | 1,093,308,000 | 703,588,000 | 787,693,000 | 905,227,000 | 989,799,000 | 631,679,000 | 640,530,000 | |||||||||||||||
| receivable from a related party | 462,000 | 8,962,000 | 462,000 | 8,000,000 | |||||||||||||||||||||
| long-term marketable securities | 60,688,000 | 82,202,000 | 23,210,000 | 31,144,000 | 75,886,000 | ||||||||||||||||||||
| other liabilities | 13,265,000 | 11,612,000 | 9,520,000 | 13,469,000 | 9,399,000 | 2,797,000 | 3,527,000 | 1,388,000 | 347,000 | ||||||||||||||||
| build-to-suit lease obligation | 8,000,000 | ||||||||||||||||||||||||
| stockholders’ equity: | |||||||||||||||||||||||||
| term loans, noncurrent | 93,392,000 | 92,908,000 | 92,416,000 | 91,791,000 | 75,017,000 | 74,997,000 | |||||||||||||||||||
| total bridgebio stockholders' equity | 163,756,000 | 265,759,000 | 380,715,000 | 408,454,000 | 459,758,000 | ||||||||||||||||||||
| total stockholders' equity | 215,813,000 | 325,606,000 | 449,018,000 | 473,733,000 | 521,697,000 | ||||||||||||||||||||
| investments in nonconsolidated entities | |||||||||||||||||||||||||
| accrued distributions to stockholders | |||||||||||||||||||||||||
| undesignated preferred stock, 0.001 par value; 25,000,000 and no shares authorized as of december 31, 2019 and 2018; no shares issued and outstanding as of december 31, 2019 and 2018 | |||||||||||||||||||||||||
| pellepharm investment | 907,000 | 7,495,000 | |||||||||||||||||||||||
| undesignated preferred stock, 0.001 par value; 25,000,000 and no shares authorized as of september 30, 2019 and december 31, 2018; no shares issued and outstanding as of september 30, 2019 and december 31, 2018 | |||||||||||||||||||||||||
| liabilities, redeemable convertible preferred units, redeemable founder units, redeemable common units, management incentive units, redeemable convertible noncontrolling interests, and members’ deficit | |||||||||||||||||||||||||
| accrued distributions to unitholders | |||||||||||||||||||||||||
| redeemable convertible preferred units | 479,044,000 | ||||||||||||||||||||||||
| redeemable founder units | 1,754,000 | ||||||||||||||||||||||||
| redeemable common units | 1,672,000 | ||||||||||||||||||||||||
| management incentive units | 6,523,000 | ||||||||||||||||||||||||
| members’ deficit: | |||||||||||||||||||||||||
| total bridgebio members’ deficit | -326,068,000 | ||||||||||||||||||||||||
| total members’ deficit | -277,677,000 | ||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred units, redeemable founder units, redeemable common units, management incentive units, redeemable convertible noncontrolling interests, and members’ deficit | 325,540,000 |
We provide you with 20 years of balance sheets for BridgeBio Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BridgeBio Pharma. Explore the full financial landscape of BridgeBio Pharma stock with our expertly curated balance sheets.
The information provided in this report about BridgeBio Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.